New hope for patients with deadly bile duct cancer
In the new study, patients diagnosed with the three main types of bile duct cancer (intrahepatic, perihilar or distal ...
The Sun27d
The 6 signs of ‘hard to spot’ bile duct cancer that kills majority of patients within a year
One or more of the following drugs will also be offered depending on the genetic profile of the tumour: futibatinib, ivosidenib, zanidatamab, trastuzumab, neratinib, encorafenib and binimetinib.
The Irish News27d
New hope for patients with deadly bile duct cancer
One or more of the following drugs will also be offered depending on the genetic profile of the tumour: futibatinib, ivosidenib, zanidatamab, trastuzumab, neratinib, encorafenib and binimetinib.
pharmaphorum7d
Rebranded Servier eyes €3bn in cancer drug sales by 2030
The latter brought in acute myeloid leukaemia (AML) and cholangiocarcinoma therapy Tibsovo (ivosidenib), which was approved as a first-line therapy for AML last year in combination with Bristol ...
pharmaphorum12d
Servier beefs up in cancer, buying Agios’ oncology business for $1.8bn
bringing the Bristol Myers Squibb-partnered Tibsovo (ivosidenib) for IDH1-mutant acute myeloid leukaemia to the US market. It also shares commercial rights to BMS’ Idhifa (enasidenib), also for ...
Pharmaceutical Technology24d
Ivosidenib by Les Laboratoires Servier for Low-Grade Glioma: Likelihood of Approval
Ivosidenib is under clinical development by Les Laboratoires Servier and currently in Phase I for Low-Grade Glioma. According to GlobalData, Phase I drugs for Low-Grade Glioma have a 96% phase ...